Immunicum Q1: Significant catalysts ahead - Redeye
Bildkälla: Stockfoto

Immunicum Q1: Significant catalysts ahead - Redeye

Redeye sees significant news flow for Immunicum in the coming six months, both in clinical development and financing.

Börsvärldens nyhetsbrev